Liraglutide Cost 2026: Brand vs. Generic Pricing Guide

Last Updated: March 2026

The landscape of GLP-1 medications for weight loss has shifted significantly in 2026, particularly for liraglutide (Saxenda). As of August 2025, Teva Pharmaceuticals launched the first FDA-approved generic version of liraglutide for weight management, initially priced at approximately $1,165 per month [1, 2]. This development marks a pivotal moment, offering a potentially more accessible option compared to the brand-name Saxenda, which carries a list price of around $1,349.02 for a 30-day supply [1].

The Brand Price: Saxenda in 2026

For many years, Novo Nordisk’s Saxenda was a leading GLP-1 agonist for chronic weight management. Approved by the FDA in 2014, it introduced a new class of medication to combat obesity [5]. In early 2026, the cash price for brand-name Saxenda remains substantial. Without insurance, patients typically face a monthly cost of approximately $1,349.02 for the required five 3mL pre-filled pens [1]. This figure represents the manufacturer’s suggested list price, which often does not reflect the final out-of-pocket cost for individuals with comprehensive insurance coverage or those enrolled in patient savings programs.

Novo Nordisk historically offered a Saxenda Savings Card, which could reduce the monthly cost for eligible patients. As of early 2026, such programs might still exist, potentially lowering the co-pay to as little as $25 per month for commercially insured patients [2]. However, these programs generally exclude patients covered by government healthcare programs like Medicare or Medicaid, leaving a significant portion of the population to contend with the full cost or seek alternative solutions.

Generic Liraglutide Arrives: A New Era for Access

The most impactful change for liraglutide pricing in 2026 is the market entry of generic versions. Teva Pharmaceuticals Inc. was the first to launch an FDA-approved generic liraglutide injection in August 2025, specifically indicated for chronic weight management in adults and adolescents [3, 4]. This was followed by Cipla USA Inc.’s launch in February 2026, further diversifying the generic market [7].

The FDA approval process for generic drugs ensures bioequivalence to the brand-name product, meaning they deliver the same clinical benefits and risks. As Managed Healthcare Executive reported on Teva’s launch, “Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight” [4].

Teva’s initial generic offering was priced at approximately $1,165 per month [2]. While this represents a reduction from the brand-name list price, it underscores that even generic GLP-1s can carry a significant cost. The introduction of multiple generic manufacturers, such as Cipla, is expected to foster increased competition, potentially leading to further price reductions over time. The addressable market for GLP-1 weight management drugs in the US was estimated at around $127 million as of December 2025 (IQVIA MAT Dec 2025), indicating substantial potential for generic growth [7].

Understanding Liraglutide’s Efficacy for Weight Loss

Liraglutide’s effectiveness for weight loss was robustly demonstrated in the SCALE (Satiety and Clinical Aspects of Liraglutide) trials. In the pivotal SCALE Obesity and Prediabetes trial, participants receiving liraglutide 3.0 mg once daily achieved an average weight loss of 8.0% from baseline, compared to 2.6% for those on placebo, over 56 weeks [5]. A greater proportion of patients on liraglutide achieved clinically meaningful weight loss, with 63.2% losing at least 5% of their body weight versus 27.1% on placebo [5]. This efficacy was accompanied by improvements in cardiometabolic risk factors.

While these results were groundbreaking at the time of Saxenda’s approval, newer GLP-1 agonists have since demonstrated higher average weight loss percentages, posing a challenge for liraglutide’s market position, even with generic pricing.

Insurance Coverage and Access Challenges

Insurance coverage for GLP-1 medications for weight loss has historically been a significant barrier. Many commercial and government insurance plans do not cover anti-obesity medications, often classifying obesity as a lifestyle condition rather than a disease requiring pharmacological treatment. This stance is slowly changing, but access remains inconsistent.

The availability of generic liraglutide might influence insurance coverage policies. Generics are typically preferred by formularies due to their lower cost. However, a generic GLP-1, even at $1,165 per month, is still an expensive drug. Payers will weigh its cost-effectiveness against its efficacy relative to newer, more potent GLP-1/GIP receptor agonists. Some plans may begin to cover generic liraglutide more readily than the brand name, while others may continue to impose strict criteria or exclude coverage altogether. Patients should verify their specific plan’s formulary and coverage criteria for generic liraglutide as it becomes more widely available.

Compounding Liraglutide: A Controversial Option

Prior to the FDA-approved generic launches, compounded versions of liraglutide were sometimes sought by patients due to the high cost and lack of insurance coverage for brand-name Saxenda. Compounding pharmacies create customized medications for individual patients, often when a commercial drug is unavailable or requires specific modifications.

However, the FDA has issued strong warnings regarding compounded GLP-1s. These products are not FDA-approved, meaning their safety, efficacy, and quality are not verified. The FDA stated, “compounded drugs are not FDA-approved. This means that compounded drugs do not undergo the same rigorous FDA safety, effectiveness, and quality reviews as FDA-approved drugs” [6]. With the advent of FDA-approved generic liraglutide from reputable manufacturers like Teva and Cipla, the risks associated with compounded versions become even less justifiable. Patients seeking liraglutide should prioritize FDA-approved brand or generic options to ensure product integrity and safety.

Liraglutide vs. Newer GLP-1s: Cost and Efficacy Comparison

The GLP-1 market has evolved rapidly, with newer medications demonstrating superior weight loss efficacy compared to liraglutide. Semaglutide (Wegovy) and tirzepatide (Zepbound) have set new benchmarks for weight reduction. A comparison highlights both the cost implications and the clinical differences:

Note: Pricing for Wegovy and Zepbound represents approximate list prices and can vary.

This table illustrates a critical trade-off: while generic liraglutide offers a lower price point than brand Saxenda, and potentially lower than brand Wegovy or Zepbound for some patients without insurance, its efficacy for weight loss is notably lower than the newer, weekly-dosed injectables. For example, in the STEP 1 trial, semaglutide 2.4 mg once weekly resulted in 14.9% weight loss versus 2.4% for placebo [8]. Tirzepatide, in the SURMOUNT-1 trial, achieved up to 22.5% weight reduction with its highest dose (15 mg) [9].

Patients and providers must weigh the cost savings of generic liraglutide against the potentially greater weight loss and convenience (weekly vs. daily injections) offered by semaglutide and tirzepatide.

Outlook for Liraglutide Pricing in the Future

The entry of multiple generic manufacturers into the liraglutide market in 2025 and 2026 signals increased competition. As more companies receive FDA approval and launch their versions, downward pressure on generic pricing is expected. This could lead to a more significant cost differential between brand-name Saxenda and its generic counterparts, making liraglutide a more affordable option for a wider range of patients.

However, the overall market for GLP-1s is dynamic. The continued rise of highly efficacious, next-generation drugs will influence demand for older, less potent options, even generics. While generic liraglutide offers an important step toward broader access, its future pricing and market share will be shaped by the interplay of competition, evolving insurance coverage, and the ongoing development of even more effective weight loss treatments.

Sources

1. Hannemann, K. (2026, March 12). Saxenda Cost 2026: $1,349 Monthly + $25 Savings Guide. PandaMeds. Retrieved from https://pandameds.com/blog/saxenda-cost/
2. Hannemann, K. (2026, March 12). Saxenda Coupon 2026: $25 Savings Card + Free Trial Guide. PandaMeds. Retrieved from https://pandameds.com/blog/saxenda-coupon/
3. Formulary Watch. (2025, August 28). FDA Approves Generic Version of Liraglutide Injection, a GLP-1 for Weight Loss. Pharmacy Times. Retrieved from https://www.pharmacytimes.com/view/fda-approves-generic-version-of-liraglutide-injection-a-glp-1-for-weight-loss
4. Formulary Watch. (2025, August 28). Teva Launches First Generic GLP-1 Drug for Obesity. Managed Healthcare Executive. Retrieved from https://www.managedhealthcareexecutive.com/view/teva-launches-first-generic-glp-1-drug-for-obesity
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England Journal of Medicine, 373(1), 11-22. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1406191
6. U.S. Food and Drug Administration. (n.d.). Drugs — Compounding and the FDA: Questions and Answers. Retrieved from https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed March 13, 2026)
7. Cipla USA Inc. (2026, February 27). Cipla Strengthens US Portfolio With The Launch Of Generic Saxenda. StockTitan. Retrieved from https://www.stocktitan.net/news/CPLFY/cipla-strengthens-us-portfolio-with-the-launch-of-generic-saxenda-my9vut3bzv1t.html
8. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989-1002. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
9. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205-216. Retrieved from [